EU approval for Relenza9th September 2006
GlaxoSmithKline has received approval by European Union regulators for the use of Relenza in 15 countries for the prevention of types A and B influenza.
Having previously been licensed just for use in adults and children aged 12 and over Relenza has also now been approved for the prevention of flu in children aged five and over in the European Union. European governments can now consider the drug for stockpiling in the event of a flu pandemic.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.